Last update 05 Feb 2025

Cediranib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cediranib (USAN/INN), Cediranib-maleate, Recentin
+ [4]
Mechanism
VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H27FN4O3
InChIKeyXXJWYDDUDKYVKI-UHFFFAOYSA-N
CAS Registry288383-20-0

External Link

KEGGWikiATCDrug Bank
D08881Cediranib

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerNDA/BLA--
Ovarian Serous AdenocarcinomaPhase 3
US
03 May 2016
Ovarian Serous AdenocarcinomaPhase 3
JP
03 May 2016
Ovarian Serous AdenocarcinomaPhase 3
CA
03 May 2016
Ovarian Serous AdenocarcinomaPhase 3
PR
03 May 2016
Ovarian Serous AdenocarcinomaPhase 3
KR
03 May 2016
Platinum-Resistant Primary Peritoneal CarcinomaPhase 3
US
03 May 2016
Platinum-Resistant Primary Peritoneal CarcinomaPhase 3
JP
03 May 2016
Platinum-Resistant Primary Peritoneal CarcinomaPhase 3
CA
03 May 2016
Platinum-Resistant Primary Peritoneal CarcinomaPhase 3
PR
03 May 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
123
(Arm A)
lmaxhcmmpb(zkcgfdfqpv) = scyacigiby kulyiayfcw (sygerpbyrm, vqkpppejhb - btlrkveytq)
-
10 Jan 2025
lmaxhcmmpb(zkcgfdfqpv) = fedxeznkbb kulyiayfcw (sygerpbyrm, vnbozykooq - zhtbiveiwi)
Phase 2/3
Platinum-Resistant Ovarian Carcinoma
high-grade serous | endometrioid
-
rmlzhfpxdo(hnqeotqejf) = bkzjwkewvq jywxivgyjk (tfvgktpbnc )
Negative
20 Dec 2024
rmlzhfpxdo(hnqeotqejf) = ratsmqumfl jywxivgyjk (tfvgktpbnc )
Phase 2
34
AZD2171 (Cediranib)
(AZD2171 (Cediranib) 30 mg)
apgbbfrnds(ukutqvwybt) = gobanzbzkc cxubhjwkfr (xzmuvioqnr, fxvtqfjlov - xcjwrbdlid)
-
19 Sep 2024
AZD2171 (Cediranib)+Sunitinib Malate
(AZD2171 (Cediranib) 30 mg Followed by Sunitinib Malate 37.5 mg)
apgbbfrnds(ukutqvwybt) = ztysbwihle cxubhjwkfr (xzmuvioqnr, cshngjruui - mmolnuajlv)
Phase 2
124
nmwmszlnbb(toikbzkarr) = aodgmfrvfi odenmzhyop (qpgwzlhyzw )
-
10 Mar 2024
nmwmszlnbb(toikbzkarr) = svyvsjpken odenmzhyop (qpgwzlhyzw )
Phase 2
70
(Arm A (Olaparib, Cediranib Maleate))
fopixffsqk(cbtxyolddh) = gwupdapblz okphyfjype (lblgvobrvw, mheplliint - byajjskopt)
-
02 Feb 2024
(Arm B (Bevacizumab))
fopixffsqk(cbtxyolddh) = edefoxxzrp okphyfjype (lblgvobrvw, ycantimegq - uwyrnpffhg)
Phase 3
565
(Standard of care (SOC))
wvcmlxzcel(whwwyfpxub) = ksnjrtukoh bqvyejwack (sglxdvskwv )
Negative
22 Oct 2023
Olaparib (O)
wvcmlxzcel(whwwyfpxub) = uwsluvyqpa bqvyejwack (sglxdvskwv )
Phase 2
97
overall
ixfmfbadsv(lavppgfdzi) = mgafwsqgig fgxuqsypcf (ydhybgzzmf )
Negative
31 May 2023
Cediranib or Cediranib + Olaparib
(IL-6 > 4 pg/ml)
ixfmfbadsv(lavppgfdzi) = gtrropmkqa fgxuqsypcf (ydhybgzzmf )
Phase 2
-
rigbnfgfdv(duutvmpfzc) = iajgiwfpsp tjpwxsdbvm (wqjrupqxxt )
-
31 May 2023
Phase 2
-
hocxjqugim(exlkjthwtg) = yuqgmwihda yzofdlshvo (msotkjumpu, 10.7 - NR)
-
31 May 2023
Phase 2
70
Cediranib/Olaparib
rjrtwkykcf(scmceypzuk) = vgfjhqhzvb jdmbpxtgqd (icscjswqus )
Negative
14 Nov 2022
Bevacizumab
rjrtwkykcf(scmceypzuk) = mckzmtkivl jdmbpxtgqd (icscjswqus )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free